Dactimicin is a pseudodisaccharide aminoglycoside distinguished by a unique formimidoyl group, offering a distinct antimicrobial profile. It demonstrates potent activity against a broad range of Enterobacteriaceae, inhibiting 90% of isolates at ≤4 µg/mL, and is more active than amikacin against species such as Klebsiella pneumoniae and Serratia marcescens. This compound retains efficacy against many strains harboring aminoglycoside-modifying enzymes including AAC(2’)-b, AAC(3)-III, -IV, and -V, and AAC(6’)-Ia/-Ib/-Ic/-II/-IV, though not those with AAC(3)-I or the bifunctional APH(2")-AAC(6')-I. Dactimicin induces a significant post-antibiotic effect, lasting up to 2.4 hours on Escherichia coli and 1 hour on Enterobacter cloacae, and shows marked synergy when combined with beta-lactams like piperacillin or ceftazidime. These characteristics make it a valuable probe for studying resistance mechanisms, particularly permeability-related defenses in Pseudomonas aeruginosa, and for evaluating combination therapy dynamics in vitro.
Marketplace OffersShowing from 1 suppliers1 SUPPLIERS